GlassScriptPhysician profile
Inez Stoltzfus
NPI 1063587558
$6,165.59
in general payments reported to CMS, 2019-2025
45 companies · $933 in 2025
The $933 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $504 · 2021: $896 · 2022: $1,030 · 2023: $1,055 · 2024: $1,017 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,004.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,187.58 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $873.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $492.15 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $309.23 | 2019-2025 | |
| Amgen INC. | $304.35 | 2019-2025 | Repatha, Evenity, Prolia |
| Lilly USA, LLC | $278.21 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $266.42 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $225.80 | 2019-2025 | Veozah, Myrbetriq |
| Biohaven Pharmaceuticals, INC. | $167.15 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $164.92 | 2019-2023 | |
| Lundbeck LLC | $148.05 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $123.89 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.77 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $119.89 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $116.82 | 2021-2025 | Rexulti, Abilify Maintena |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inez Stoltzfus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.